Lysosomal has raised $20m in a round backed by pharmaceutical firms Roche, Eli Lilly and Sanofi, all of which also contributed to its $4.8m seed round.

Lysosomal Therapeutics, a US-based pharmaceutical company focused on neurodegenerative diseases, secured $20m yesterday in a series A round featuring the corporate venturing units of pharmaceutical companies Eli Lilly, Roche and Sanofi.

Lilly Ventures, Roche Venture Fund and Sanofi-Genzyme BioVentures were joined by Hatteras Venture, Atlas Venture, Partners Innovation Fund and Orion Equity Partners, as well as company co-founders Henri Termeer and Bob Carpenter.

Lysosomal previously secured $4.8m in a May 2014 seed round led by Atlas that included Eli Lilly,…